Deciphera Pharmaceuticals Stock (NASDAQ:DCPH), Analyst Ratings, Price Targets, Predictions

The latest price target for Deciphera Pharmaceuticals (NASDAQ: DCPH) was reported by Guggenheim on April 30, 2024. The analyst firm set a price target for $0.00 expecting DCPH to fall to within 12 months (a possible -100.00% downside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Deciphera Pharmaceuticals (NASDAQ: DCPH) was provided by Guggenheim, and Deciphera Pharmaceuticals downgraded their neutral rating.

The last upgrade for Deciphera Pharmaceuticals Inc happened on April 30, 2024 when Barclays raised their price target to $26. Barclays previously had an underweight for Deciphera Pharmaceuticals Inc.

The last downgrade for Deciphera Pharmaceuticals Inc happened on April 30, 2024 when Guggenheim changed their price target from N/A to N/A for Deciphera Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Deciphera Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Deciphera Pharmaceuticals was filed on April 30, 2024 so you should expect the next rating to be made available sometime around April 30, 2025.

While ratings are subjective and will change, the latest Deciphera Pharmaceuticals (DCPH) rating was a downgraded with a price target of $0.00 to $0.00. The current price Deciphera Pharmaceuticals (DCPH) is trading at is $25.24, which is out of the analyst’s predicted range.